Mohammad Ehsanul Karim

Dr. Mohammad Ehsanul Karim

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2012 in JAMA
Verified
Journal Article
Closed access
PDF file
ASAfsaneh Shirani
Afsaneh Shirani
YZYinshan Zhao
Yinshan Zhao
MKMohammad Ehsanul Karim
Mohammad Ehsanul Karim
CECharity Evans
Charity Evans
EKElaine Kingwell
Elaine Kingwell
HTHelen Tremlett
Helen Tremlett
Research from JAMA — Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis

25 July 2016 in American Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
MKMohammad Ehsanul Karim
Mohammad Ehsanul Karim
PGPaul Gustafson
Paul Gustafson
JPJohn Petkau
John Petkau
HTHelen Tremlett
Helen Tremlett
TBThe Long-Term Benefits
The Long-Term Benefits
In time-to-event analyses of observational studies of drug effectiveness, incorrect handling of the period between cohort entry and first treatment exposure during follow-up may result in immortal time bias. This bias can be eliminated by acknowledging a change in treatment exposure status with time-dependent analyses, such as fitting a time-dependent Cox model. The prescription time-distribution matching (PTDM) method has been proposed as a simpler approach for controlling immortal time bias. Using simulation studies and theoretical quantification of bias, we compared the performance of the PTDM approach with that of the time-dependent Cox model in the presence of immortal time. Both assessments revealed that the PTDM approach did not adequately address immortal time bias. Based on our simulation results, another recently proposed observational data analysis technique, the sequential Cox approach, was found to be more useful than the PTDM approach (Cox: bias = −0.002, mean squared error = 0.025; PTDM: bias = −1.411, mean squared error = 2.011). We applied these approaches to investigate the association of β-interferon treatment with delaying disability progression in a multiple sclerosis cohort in British Columbia, Canada (Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study, 1995–2008).

6 August 2019 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
MAMohammad Atiquzzaman
Mohammad Atiquzzaman
MKMohammad Ehsanul Karim
Mohammad Ehsanul Karim
JKJacek Kopec
Jacek Kopec
HWHubert Wong
Hubert Wong
AAAslam Anis
Aslam Anis

17 June 2014 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MKMohammad Ehsanul Karim
Mohammad Ehsanul Karim
PGPaul Gustafson
Paul Gustafson
JPJohn Petkau
John Petkau
YZYinshan Zhao
Yinshan Zhao
ASAfsaneh Shirani
Afsaneh Shirani
HTHelen Tremlett
Helen Tremlett
Longitudinal observational data are required to assess the association between exposure to β-interferon medications and disease progression among relapsing-remitting multiple sclerosis (MS) patients in the “real-world” clinical practice setting. Marginal structural Cox models (MSCMs) can provide distinct advantages over traditional approaches by allowing adjustment for time-varying confounders such as MS relapses, as well as baseline characteristics, through the use of inverse probability weighting. We assessed the suitability of MSCMs to analyze data from a large cohort of 1,697 relapsing-remitting MS patients in British Columbia, Canada (1995–2008). In the context of this observational study, which spanned more than a decade and involved patients with a chronic yet fluctuating disease, the recently proposed “normalized stabilized” weights were found to be the most appropriate choice of weights. Using this model, no association between β-interferon exposure and the hazard of disability progression was found (hazard ratio = 1.36, 95% confidence interval: 0.95, 1.94). For sensitivity analyses, truncated normalized unstabilized weights were used in additional MSCMs and to construct inverse probability weight-adjusted survival curves; the findings did not change. Additionally, qualitatively similar conclusions from approximation approaches to the weighted Cox model (i.e., MSCM) extend confidence in the findings.

1 March 2018 in Epidemiology
Verified
Journal Article
Closed access
PDF file
MKMohammad Ehsanul Karim
Mohammad Ehsanul Karim
MPMenglan Pang
Menglan Pang
RPRobert W. Platt
Robert W. Platt
The use of retrospective healthcare claims datasets is frequently criticized for the lack of complete information on potential confounders. Utilizing patient’s health status-related information from claims datasets as surrogates or proxies for mismeasured and unobserved confounders, the high-dimensional propensity score algorithm enables us to reduce bias. Using a previously published cohort study of post-myocardial infarction statin use (1998 - 2012), we compare the performance of the algorithm with a number of popular machine learning approaches for confounder selection in high-dimensional covariate spaces: random forest, least absolute shrinkage and selection operator, and elastic net. Our results suggest that, when the data analysis is done with epidemiologic principles in mind, machine learning methods perform as well as the high-dimensional propensity score algorithm. Using a plasmode framework that mimicked the empirical data, we also showed that a hybrid of machine learning and high-dimensional propensity score algorithms generally perform slightly better than the both in terms of mean squared error, when a bias-based analysis is used.

1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ASAfsaneh Shirani
Afsaneh Shirani
YZYinshan Zhao
Yinshan Zhao
JPJohn Petkau
John Petkau
PGPaul Gustafson
Paul Gustafson
MKMohammad Ehsanul Karim
Mohammad Ehsanul Karim
HTHelen Tremlett
Helen Tremlett
Background. We examined (1) patient characteristics and disease-modifying drug (DMD) exposure in late-onset (LOMS, ≥50 years at symptom onset) versus adult-onset (AOMS, 18–<50 years) MS and (2) the association between interferon-beta (IFNβ) and disability progression in older relapsing-onset MS adults (≥50 years).Methods. This retrospective study (1980–2004, British Columbia, Canada) included 358 LOMS and 5627 AOMS patients. IFNβ-treated relapsing-onset MS patients aged ≥50 (regardless of onset age, 90) were compared with 171 contemporary and 106 historical controls. Times to EDSS 6 from onset and from IFNβeligibility were examined using survival analyses.Results. LOMS patients (6%) were more likely to be male, with motor onset and a primary-progressive course, and exhibit faster progression and were less likely to take DMDs. Nonetheless, 57% were relapsing-onset, of which 31% were prescribed DMDs, most commonly IFNβ. Among older relapsing-onset MS adults, no significant association between IFNβexposure and disability progression was found when either the contemporary (hazard ratio [HR]: 0.46; 95% CI: 0.18–1.22) or historical controls (HR: 0.54; 95% CI: 0.20–1.42) were considered.Conclusion. LOMS differed clinically from AOMS. One-third of older relapsing-onset MS patients were prescribed a DMD. IFNβexposure was not significantly associated with reduced disability in older MS patients.